Pharmacyl

Pharmacyl is a biotechnology company focused on the development of novel therapeutic compounds targeting the endocannabinoid system. The company specializes in the synthesis and optimization of small molecule ligands for cannabinoid receptors to treat a variety of conditions including chronic pain, inflammation, and neurological disorders. By leveraging advanced medicinal chemistry, Pharmacyl aims to create highly selective treatments that minimize side effects associated with traditional cannabinoid therapies. Their current research efforts are primarily in the pre-clinical stage, focusing on establishing proof-of-concept for their lead candidates.